Why it’s up 1.43% today
- Creative Medical Technology Holdings Inc (NASDAQ: CELZ) stock price rose 1.43% today. That is why.
The stock price of Creative Medical Technology Holdings Inc (NASDAQ: CELZ) – a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology and orthopedics – rose 1.43% today. Investors have responded positively to Creative Medical Technology by announcing that the company has signed an agreement with Greenstone Biosciences in Palo Alto, California to develop a human induced pluripotent stem cell (iPSC) pipeline for the platform. ImmCelz of the company. This project will be identified as iPScelz for future reference.
Human iPScs are genetically reprogrammed to differentiate into a wide range of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a unique source of cells that could be used to replace those lost to damage. or diseases. And beyond the therapeutic benefits offered by iPSC, the next-generation iPScelz pipeline for ImmCelz will enable large-scale production capacity and sustainability, while helping to reduce long-term manufacturing costs.
“This is a great collaboration that translates our expertise in iPSC technology to accelerate therapies that improve patient care – from bench to bedside.”
– Dr. Joseph C. Wu, co-founder of Greenstone Biosciences – who is the director of the Stanford Cardiovascular Institute, and Simon H. Stertzer, MD, professor of medicine and radiology at Stanford University.
“We are excited to complement and expand our current work with the addition of Dr. Joseph Wu and the Greenstone team at the Alexandria Center for Life Sciences (ACLS). Greenstone brings extensive experience in the development of iPSC and related technologies. In combination with ongoing work at the University of Miami, we believe our ImmCelz platform has tremendous potential to improve patient outcomes across multiple indications, including stroke, type I diabetes, heart disease, liver disease and kidney disease.
— Timothy Warbington, company president and CEO
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.